Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2020

View Archived Issues

Macrolide resistance mechanism rescues mRNA from ribosome

Results from the NCI-MATCH subprotocol using T-DM1 in HER2-amplified histologies

European Commission grants marketing authorization for Isturisa

Lung cancer treatment options much improved, but resistance remains

New PCSK9 inhibitors discovered at Ra Pharmaceuticals

Jiangsu Vcare Pharmatech patents EGFR inhibitors

miR-107 as a new target for overcoming chemoresistance in CRC

Medshine Discovery identifies new IRAK-4 inhibitors

Novel TMEM16A potentiator shows promise in models of CF

Janssen R&D Ireland and Johnson & Johnson disclose anti-HBV compounds

Henan Tiansheng Taifeng Pharmaceutical Technology discovers compounds for HBV treatment

HDAC blockade seen to restore cardiopulmonary function in felines

New nonviral nanoparticles are safe and effective for gene therapy in pediatric brain cancer models

Phase IIb study of nebulized ensifentrine meets primary endpoints

Vertex's VX-814 enters phase II development for alpha1-antitrypsin deficiency

Sintilimab regimen meets primary endpoint in phase III non-small cell lung cancer trial

Preliminary findings from phase I study of Spero's SPR-206 support advancement of program

Neurodegeneration treatment candidate IW-6463 well tolerated in phase I study

GeneTx Biotherapeutics cleared to begin phase I/II study of GTX-102 in Angelman syndrome

Tmunity Therapeutics initiates phase I study of CART-TnMUC1

ART1, a novel therapeutic target in EGFR-mutated lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...